Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-02-12
1999-04-06
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 25, 514 27, 514 28, 514 29, 514 30, 514 31, 435184, 530351, 530396, 530399, A61K 31705, A01N 4500, C07K 100
Patent
active
058918558
ABSTRACT:
This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL,-1.alpha., IL-1.beta. and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.
REFERENCES:
patent: 5545623 (1996-08-01), Matsumori
patent: 5627195 (1997-05-01), Hu
Cooper and Barondes, "Evidence for Export of a Muscle Lectin from Cytosol to Extracellular Matrix and for a Novel Secretory Mechanism," Journal of Cell Biology 110: 1681-1691, 1990.
Florkiewicz et al., "Multiple Forms of bFGF: Differential Nuclear and Cell Surface Localizaton," Growth Factors 4:265-275, 1991.
Florkiewicz et al., "Quantitative Export of FGF-2 Occurs Through an Alternative, Energy-Dependent, Non-ER/Golgi Pathway," Journal of Cellular Physiology 162: 388-399, 1995.
Jackson et al., "Heat shock induces the release of fibroblast growth factor 1 from NIH 3T3 cells," Proc. Natl. Acad. Sci. USA 89: 10691-10695, 1992.
Jackson et al., "The Release of Fibroblast Growth Factor-1 from NIH 3T3 Cells In Response to Temperature Involves the Function of Cysteine Residues," Journal of Biological Chemisty 270(1): 33-36, 1995.
Mignatti et al., "Basic Fibroblast Growth Factor, a Protein Devoid of Secretory Signal Sequence, Is Released by Cells via a Pathway Independent of the Endoplasmic Reticulum-Golgi Complex," Journal of Cellular Physiology 151: 81-93, 1992.
Repke et al., "Potential suitablility of NA.sup.+ /K.sup.+ -transporting ATPase in pre-screens for anti-cancer agents," Anti-Cancer Drug Design 10: 177-187, 1995.
Rubartelli et al., "A novel secretory pathway for interleukin-1.beta., a protein lacking a signal sequence," EMBO Journal 9(5): 1503-1510, 1990.
Rubartelli et al., "Secretion of Thioredoxin by Normal and Neoplastic Cells through a Leaderless Secretory Pathway," Journal of Biological Chemistry 267(34): 24161-24164, 1992.
Rubartelli et al., "Post-Translational Regulation of Interleukin 1.beta. Secretion," Cytokine 5(2): 117-124, 1993.
Siders and Mizel, "Interleukin-1.beta. Secretion. A Possilbe Multistep Process that is Regulated in a Cell Type-Specific Manner," Journal of Biological Chemistry 270(27): 16258-16264, 1995.
Katahira et al. Chemotherapy Jul. 1991, 39(7), 678-686.
Callard et al. "The Cytokine FactsBook" Academic Press Limited, London, 1994, pp. 31-38.
Brooks, D., "Protein Secretion by the Rat Epididymis Can Be Selectively Modified in Vitro by Local Anesthetics, Glucose Deprivation, Dinitrophenol, Ouabain and Ionophores," J. Androl. 5: 351-360, 1984.
Crutchely and Smariga, "Monovalent Cation Dependence of Tissue Plasminogen Activator Synthesis by HeLa Cells," Journal of Biological Chemistry 262(7): 3017-3021, 1987.
Fonda Kathleen K.
The Scripps Research Institute
LandOfFree
Inhibitors of leaderless protein export does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of leaderless protein export, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of leaderless protein export will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1371446